Age-Related Macular Degeneration Drug Discovery Service
As a globally reputable service provider, Creative Biolabs is committed to providing customers around the world with one-stop age-related macular degeneration (AMD) research services to facilitate your project progress.
Introduction of AMD
AMD is a common eye disease that affects central vision. Additionally, it occurs when the macula of the retina wears down and occurs with age. Generally, AMD does not cause blindness, but it can cause serious vision problems. In addition, AMD is a major cause of vision loss in the elderly, imposing a heavy medical and socioeconomic burden. There are two main types of AMD: dry and wet. Most AMD patients have the dry form. Vision loss in this condition is usually gradual. The wet type is less common, but it usually causes more severe vision loss in patients than dry AMD. AMD is closely associated with a variety of factors, such as dysregulation of complement, lipids, angiogenesis, inflammation, and extracellular matrix pathways.
Fig.1 Progression of signs of AMD over time. (Lim, 2012)
Therapeutic Approaches for AMD
Treatment strategies for AMD require a combination of factors, including diet, lifestyle, pharmacological interventions and genetics.
- Drug therapy
One of the research areas focuses on statin therapy, which has been shown to be associated with possible drusen regression but needs to be further explored. In addition, there is evidence that vascular endothelial growth factor (VEGF) inhibitors and corticosteroid drugs inhibit neovascularization. Notably, two commonly used anti-VEGF antibody drugs have been found to have great potential in the treatment of AMD. What's more, other drugs, such as vitamins and minerals, are effective in preventing the progression of advanced ARMD.
- Cell-based therapies
Over the past few decades, much effort has been devoted to developing new and more effective treatments, such as the implantation of cells. There are two types of cell-based therapies: stem cell therapy and non-stem cell therapy. Stem cell therapy is based on the delivery of new retinal pigment epithelium (RPE) cells into the subretinal space to improve the health of retinal photoreceptor cells. A non-stem cell approach involves implanting cells that generate the protective factors that are lacking.
- Gene therapy
For AMD, the primary targets of gene therapy are RPE cells and photoreceptor cells. With currently approved ocular gene therapy treatments, subretinal injections are becoming more standard. There are three commonly used vectors in gene therapy: recombinant adeno-associated virus (rAAV) vectors, adenovirus (Ad), and integration-deficient lentivirus (IDLV). Moreover, several lines of evidence demonstrate the safety of the subretinal administration of the gene. Therefore, gene therapy is expected to be an important alternative for the therapy of AMD.
Animal Models of AMD
The multifactorial etiology of AMD and the lack of effective treatments have prompted the development of animal models as research and drug discovery tools. Currently, several rodent models have been developed that recapitulate key features of AMD and provide insights into its underlying pathology. These models have various features associated with AMD, including oxidative stress, hypoxia, immune dysregulation, genetic mutations, and environmental risk factors, which have contributed to significant progress in understanding the disease and identifying new therapeutic targets.
Mechanism of Action (MoA) Studies of Pathophysiology
- Oxidative stress
Oxidative stress has been identified as a key trigger in the pathogenesis of AMD. Elevated levels of multiple antioxidant enzymes and heat shock proteins in AMD donor RPE provide indirect evidence for increased oxidative stress. Furthermore, oxidative stress plays an important role in AMD due to the relatively high oxygen consumption of the retina.
- Defects in RPE mitochondria drive AMD pathology
RPE mitochondrial defects are closely linked to AMD pathology. There is evidence that disruption of RPE mitochondrial structure is accompanied by alterations in the content of various mitochondrial proteins, as well as increased Mitochondrial DNA (mtDNA) damage associated with disease severity. In addition, damage to mitochondria will affect ATP production, leading to a bioenergetic crisis in the RPE.
Services for AMD Research
- In Vitro Services
- In Vivo Services
- Ex Vivo Services
- Discovery Services
- Development Services
If you have any difficulties with your AMD research, please contact us for professional assistance and customized plans.
Reference
- Lim, L. S.; et al. Age-related macular degeneration. The Lancet. 2012, 379(9827): 1728-1738.

- iNeuMab™ Rabbit Anti-LRRK2 Monoclonal Antibody (CBP1887) (Cat#: NAB-08-PZ735)
- iNeuMab™ Mouse Anti-LRP1 Monoclonal Antibody (CBP3363) (Cat#: NAB-0720-Z6479)
- Mouse Anti-SCN5A Monoclonal Antibody (CBP708) (Cat#: NAB-0720-Z2720)
- iNeuMab™ Anti-F-Spondin/SPON1 Antibody, Clone 3F4 (Cat#: NRZP-0822-ZP4740)
- Mouse Anti-Human α-Synuclein Phospho (Tyr39) (CBP3706) (Cat#: NAB201250LS)
- iNeuMab™ Mouse Anti-SHANK3 Monoclonal Antibody (CBP929) (Cat#: NAB-0720-Z3477)
- iNeuMab™ Mouse Anti-EFNB2 Monoclonal Antibody (CBP1159) (Cat#: NAB-0720-Z4396)
- iNeuMab™ Rabbit Anti-Alpha-synuclein (CBP1631) (Cat#: NAB-08-PZ079)
- Human Microglia Cell Line HMC3, Immortalized (Cat#: NCL-2108P38)
- Rat Microglia Cell Line HAPI, Immortalized (Cat#: NCL2110P015)
- Rat Schwann Cells RSC96, Immortalized (Cat#: NCL-2108P21)
- Human Brain Microvascular Endothelial Cells (Cat#: NCL-2103-P133)
- Mouse Glioma Cell Line GL261 (Cat#: NCL-2108P28)
- Rat Muller Cell (Cat#: NCL2110P040)
- Green Fluorescent Tau cell Line (Cat#: NCL2110P219)
- Rat Immortalized Retinal Muller Cell Line rMC-1 (Cat#: NCL-2106-S93)
- iNeu™ Human Sensory Neurons (Cat#: NCL-2103-P62)
- Rat Olfactory Ensheathing Cells (Cat#: NRZP-1122-ZP162)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- Dextran, NHS Activated (Cat#: NRZP-0722-ZP124)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- App Rat amyloid beta (A4) precursor protein (App)(NM_019288) ORF clone, Untagged (Cat#: NEP-0421-R0053)
- Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Rat Parkinson disease (autosomal recessive, juvenile) 2, parkin (Park2) (NM_020093) ORF clone/lentiviral particle, Myc-DDK Tagged (Cat#: NEP-0621-R0041)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroPro™ Anti-ASA BBB Shuttle Protein (Cat#: NRZP-0423-ZP504)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein (Cat#: NRZP-0423-ZP499)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP509)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-EPO BBB Shuttle Protein (Cat#: NRZP-0423-ZP508)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP501)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)
- NeuroPro™ Anti-SGSH BBB Shuttle Protein (Cat#: NRZP-0423-ZP505)